Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

GlobeNewswire

BEERSE, BELGIUM, Oct. 25, 2026 -- Johnson & Johnson today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study with first-line subcutaneous RYBREVANT®▼ (amivantamab) plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in patients with advanced recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) other than human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).1 These findings support the ongoing pivotal Phase 3 OrigAMI-5 study and further expand the clinical development programme for subcutaneous amivantamab for patients with head and neck cancer.

  1. FinanceSHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Honeywell Aerospace, Inc. (NASDAQ: HONA) — Investors Who Suffered Losses Are Encouraged to Contact the Firm.New class action for Honeywell (HONA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/23/2026
  2. LegalBronstein, Gewirtz & Grossman LLC Urges AST SpaceMobile, Inc. Investors to Act: Class Action Filed Alleging Investor HarmNew class action for AST SpaceMobile, Inc. urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 12/13/2026
  3. EnergyBronstein, Gewirtz & Grossman LLC Urges FuelCell Energy, Inc. Investors to Act: Class Action Filed Alleging Investor HarmNew class action for FuelCell (FCEL) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/10/2026
  4. FinanceOruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
  5. FinanceROSEN, SKILLED INVESTOR COUNSEL, Encourages Gildan Activewear Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GILWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gildan Activewear Inc. (NYSE: GIL) between February 19, 2025 and June 15, 2026, both dates inclusive (the “Class Period”), of the important December 14, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
  6. HealthcareRoche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancerCompanies: Roche HoldingBasel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).1,2 Participants treated with divarasib monotherapy lived significantly longer, lowering the risk of death by 44% compared with sotorasib or adagrasib (overall survival, OS, HR 0.56, [95% CI: 0.41-0.78], p=0.0005).1,2 Median OS for divarasib is currently approximately 18 months, compared to 12 months for the control arm (see table below).1,2 No new safety findings were observed with divarasib and the most common treatment-related adverse events (TRAEs) were mainly low grade and manageable.1,2 These data were presented as a late-breaking abstract during a Presidential Symposium at the 2026 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine.1,2